Introduction
Acute Respiratory Distress Syndrome (ARDS) and subsequent multi-organ failure (MOF) are primary drivers of mortality in intensive care units, a challenge exacerbated by the COVID-19 pandemic. While neutrophils are vital for pathogen defense, their dysregulation in hyperinflammatory states leads to "innocent bystander" tissue injury. This study identifies a specific, pathogenic subset of neutrophils—characterized by the expression of the Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR)—that is associated with disease severity and mortality. These "rogue" neutrophils are apoptosis-resistant, contributing to persistent inflammation, but can be targeted for clearance using a humanized anti-DEspR antibody.
Identifying the Pathogenic Neutrophil Subset
The researchers hypothesized that DEspR, a receptor known to promote survival in cancer cells, might also confer apoptosis resistance to a subset of neutrophils in ARDS. Using a combination of flow cytometry, immunofluorescence, and single-cell RNA sequencing (scRNA-seq), they identified circulating DEspR+CD11b+ activated neutrophils (DEspR+actNs) as key players.
In clinical cohorts of both classic ARDS and COVID-19 ARDS, the presence of these cells correlated strongly with poor outcomes. Specifically, the number of DEspR+ activated neutrophils showed a strong negative correlation with ICU-free days (Spearman $r = -0.80, P = 0.0002$). Furthermore, high levels of these cells were predictive of lower survival probability.
Mechanisms of Persistent Inflammation
The study revealed that DEspR+ neutrophils in severe COVID-19 patients exhibit an autocrine loop, expressing both the receptor and its ligand, Endothelin-1. This self-sustaining signal likely contributes to their survival. Additionally, these cells are closely linked to NETosis—the release of neutrophil extracellular traps—which can clog microvessels and cause secondary organ damage. Unlike normal neutrophils, this DEspR+ subset resists programmed cell death, allowing them to remain active in the circulation and lungs far longer than necessary.
A Novel Therapeutic Strategy: Inducing Subset-Specific Apoptosis
A critical finding of this research is that the apoptosis resistance of DEspR+ neutrophils can be reversed. The team utilized hu6g8, a humanized anti-DEspR-IgG4 S228P antibody, in ex vivo experiments. Treatment of ARDS patient blood and non-human primate (NHP) neutrophils with hu6g8 successfully induced apoptosis.
Live-cell imaging confirmed that the antibody engages the target and is internalized, triggering the cell's death machinery. This approach offers a significant advantage over broad immunosuppression: it specifically targets the "rogue" subset responsible for tissue damage while potentially leaving the broader immune response intact.
Conclusion and Future Outlook
This study differentiates DEspR+actNs as a targetable neutrophil subset associated with ARDS severity. By identifying a mechanism to "shut down" these hyperinflammatory cells, the researchers have proposed a potential new therapeutic paradigm for severe respiratory failure.
While the results are promising, the authors note that the pilot study's small sample size ($n=30$) necessitates larger clinical trials. Future work will also need to address the in vivo efficacy of hu6g8 and monitor for potential off-target effects, particularly in the kidneys where DEspR is also expressed. Nonetheless, the identification of DEspR as both a biomarker and an actionable target marks a significant step forward in managing critical illness.
Summary updated